Survivin: Potential role in diagnosis, prognosis and targeted therapy of gastric cancer

Table 1 Expression of survivin in gastric cancer in association with cancer progression and malignancy

Author /Year	Number of patients	Diagnostic technique	Survivin expression	Correlation with (P value)	References
LUCD /1998	174	IHC	60 (34.5%)	Apoptotic index (< 0.001)	20
Okada E /2001	133	IHC	60 (82.0%)	—	21
Krieg A /2002	30	RT-PCR	30 (100.0%)	Tumor stage (0.033)	22
Yu J /2002	50	RT-PCR/IHC	34 (68.0%)	Apoptotic index (0.02), Cox-2 overexpression (0.001)	15
Tsuburaya A /2002	25	RT-PCR	16 (64.0%)	Depth of tumor (< 0.05) peritoneal metastasis (< 0.05)	23
Wakana Y /2002	42	RT-PCR/IHC	—	Apoptotic index (< 0.05), histological type (< 0.001)	24
Miyachi /2003	107	RT-PCR	105 (98.1%)	Lymph node metastasis (< 0.01)	25
Yao XQ /2004	120	IHC	59 (49.2%)	Histological subtypes, lymph node metastasis apoptotic index (< 0.05)	26
Wang ZN /2004	48	RT-PCR	32 (66.7%)	Depth of cancer invasion, peritoneal lavage fluid, lymph node metastasis, TNM stage (< 0.05)	16
Meng H /2005	77	RT-PCR	77 (100.0%)	Survival rate (< 0.01)	27
				Docetaxel-resistance (< 0.05)	28
Sun YS /2006	96	IHC	55 (57.2%)	Serosal infiltration, lymphatic invasion, regional lymph node metastasis, TNM stage, distant metastasis, survival rate (< 0.05), VEGF-C (< 0.001)	29
Lee GH /2006	106	IHC	53 (50.0%)	Tumor size (0.011), tumor stage (0.002), depth of invasion (0.004), poor survival (0.046), lymph node metastasis (0.020)	30

IHC: Immunohistochemistry; RT-PCR: Reverse transcriptase PCR.